A phase II, multicenter, open-label, randomized trial of pegfilgrastim for patients with alcohol-associated hepatitis

Timothy Morgan,Aliya Asghar,John Tayek,Danh Nguyen,M. Wayne Fleischman,John Donovan, Joseph Alcorn,Daniel Chao,Andrew Stolz

JOURNAL OF HEPATOLOGY（2022）

引用 6|浏览14

暂无评分

摘要

was provided by the United States National Institutes of Health and National Institute on Alcohol Abuse and Alcoholism U01-AA021886 and U01-AA021884.

查看译文

关键词

ACLF, acute on chronic liver failure,AH, alcohol-related hepatitis,AKI, acute kidney injury,Alcoholic hepatitis,CTCAE, common terminology criteria for adverse events,DF, discriminant function,DSMB, data safety monitoring board,FDA, food and drug administration,FU, follow-up,GCSF, granulocyte colony stimulating factor,HIV, human immunodeficiency virus,HRS, hepatorenal syndrome,INR, international normalized ratio,NIAAA, national institute on alcohol abuse and alcoholism,Pegfilgrastim,Phase II,Randomized clinical trial,SD, standard deviation,SOC, standard of care,WBC, white blood cell count

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要